Previous posts have discussed the contentious issue of which CLL patients in the UK are classed as Extremely Vulnerable and are therefore eligible for government support. Members on watch and wait in Scotland have been excluded as they are not among those "who are at any stage of treatment". While few members in England have said the same, many reported not receiving the NHS shielding letter.
Apparently NHS Scotland adopted the guidance from NHS UK, which also included the qualifier "who are at any stage of treatment", but interpreted it in a literal and restrictive way. Curiously, earlier NHS guidance had omitted the offending phrase, so that anyone with blood cancer would then have been considered Extremely Vulnerable.
Confused? Join the club.
NHS England has recently clarified "the conditions that put someone at highest risk of being severely ill if they were to catch COVID-19" in a letter to NHS practitioners. These include people " ...who are at any stage of treatment" but crucially with a footnote "This means before, during or after treatment, including those being managed expectantly".
It could not be any clearer: NHS England practitioners are directed to include all CLL patients as being at highest clinical risk to COVID-19, i.e. extremely vulnerable. If you are on watch and wait, you may be a footnote, but you're in. Where that leaves patients in Scotland who knows, I guess it depends on whether or not NHS Scotland chooses to adopt the guidance.
The new clarification can be downloaded from bloodcancer.org.uk/support-...
(Copied and pasted)
To: Cancer Alliance leadership teams
Cc: regional teams
7 May 2020
Dear Colleagues,
We are contacting you to ask for your help in reminding the clinical teams in your areas of their role in identifying patients at highest clinical risk to COVID-19 and advising them to shield. The list of conditions that put someone at highest risk of being severely ill if they were to catch COVID-19 is set out in Annex 1.
(letter continues)
Kind regards,
(Signed)
Professor Peter Johnson
National Clinical Director for Cancer
----------------------
Annex 1:
1. Solid organ transplant recipients.
2. People with specific cancers:
o people with cancer who are undergoing active chemotherapy
o people with lung cancer who are undergoing radical radiotherapy
o people with cancers of the blood or bone marrow such as leukaemia,
myelodysplastic syndromes, lymphoma or myeloma who are at any stage of
treatment(1)
o people having immunotherapy or other continuing antibody treatments for
cancer
o people having other targeted cancer treatments which can affect the immune
system, such as protein kinase inhibitors or PARP inhibitors
o people who have had bone marrow or stem cell transplants in the last 6
months, or who are still taking immunosuppression drugs(2)
3. People with severe respiratory conditions including all cystic fibrosis, severe asthma and severe chronic obstructive pulmonary (COPD).
4. People with rare diseases that significantly increase the risk of infections (such as SCID, homozygous sickle cell).
5. People on immunosuppression therapies sufficient to significantly increase risk of infection.
6. Women who are pregnant with significant heart disease, congenital or acquired.
_________________________________
(1) This means before, during or after treatment, including those being managed expectantly
(2) When applying these criteria locally, clinicians should take into account the new Covid-19 NICE guidance on haemotopoietic stem cell transplantation which states that patients should follow shielding advice:
• if they had an autologous HSCT within the last year
• if they had an allogeneic HSCT within the last 2 years, or they are having continuous immunosuppressive therapy, they have chronic graft versus host disease (GvHD) or there is evidence of ongoing immunodeficiency (or for other extremely vulnerable groups based on clinical assessment).